American Cryostem Exclusive Interview on Regenerative/Personalized Medicine for the Interlinked Investment News Channel on InterlinkedTV

Share Article

American Cryostem, a pioneer in the fields of Regenerative and Personalized Medicine, granted an exclusive Interview for the Interlinked Investment News Channel on InterlinkedTV during recent FSXinterlinked Investment Conference

American Cryostem Core Tissue Processing Technology

American Cryostem's Chairman and CEO, John Arnone, granted Interlinked an exclusive interview for the FSXinterlinked channel on InterlinkedTV.

American CryoStem Corporation, a pioneer in the fields of Regenerative and Personalized Medicine, was one of the presenting companies interviewed for InterlinkedTV at the recent FSXinterlinked Investment Conference.

Mr. Arnone explained during the interview that science is currently able to cure about 100 diseases using adipose derived stem cells, adding that almost anyone that does not have their cord blood is a candidate for regenerative medicine. About 99 percent of the population does not have cord blood stored and more specifically those with a family history of cancer, diabetes, etc. should consider this as an insurance policy, stating "science shows that a younger cell injected back into in older body will get the cells in that particular area to regenerate."

American Croystem has about 150 cosmetic surgeons whom during a quick 30-minute visit can collect the adipose tissue, place it into a collection canister supplied by American Cryostem and ship it to their laboratories. Once the tissue arrives at the laboratory, it is processed and cryo-preserved and should it be needed in the future, the patient or physician simply requests the stem cells.

Mr. Arnone stated that American Cryostem has a numerous research library on their website and also supply URLs of other massive databases that show what can be done with the cells. He added "One of the most interesting pieces is that, over the last 6 months or so, what has developed is that for plastic surgeons and cosmetic surgeons, one of the hottest procedure has become fat transfer." Autologous fat transfer is an increasingly preferred procedure by patients looking for natural augmentation and correction procedures. Storing your adipose tissue for cosmetic enhancements provides a person with many benefits not available during one-time fat grafting procedures.

The interview was conduced by FSXinterlinked host, Mr. Michael Fugler, and is available on the FSXinterlinked channel on InterlinkedTV.

American CryoStem is a developer, marketer and global licensor of patented adipose tissue-based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities.

About FSXinterlinked Investment Conference.
FSXinterlinked is the premier investment conference organization in the United States. Founded as Financial Services Exchange (FSX) in 1983, it is a national organization comprised of independent FINRA broker/dealer firms and private equity fund managers. With quarterly investment conferences hosted throughout the U.S., FSXinterlinked creates a forum for emerging growth companies seeking capital to present to a nationwide network of financial investment professionals.

The FSXinterlinked network of independent broker/dealers has a combined sales force of thousands of accredited investors looking to invest in companies of all sizes and industries. To date, more than $3 billion has been raised for presenting companies through the FSXinterlinked network. FSXinterlinked’s exclusive network of FINRA firms makes the investment conferences the ideal setting for private and public companies seeking mezzanine financing, funding for private placements, IPOs, secondary financing and pipes, exposure, and more. For more information, visit

Interlinked is a global investment community of accredited investors, emerging growth companies, and resource partners. Interlinked offers an efficient way for companies to maximize exposure and access a private network of funding sources and verified service providers. For investors, Interlinked provides a secure environment to find, vet and engage companies, and communicate with members. Interlinked gives members exclusive access to a proprietary investment platform, which integrates virtual data rooms, video news, a service provider marketplace, an event directory, and customized marketing services, including email marketing, video production, public relations and more. For more information visit:

Safe Harbor Statement
This press release may contain information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release, including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Delray Wannemacher
+1 (281) 940-1555
Email >

John Arnone
since: 08/2012
Like >

Visit website